Partner Investment Management’s Heron Therapeutics HRTX Stock Holding History

Partner Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-49,038	Closed	-$679K	–	91
2017 Q2	$679K	Sell	49,038 -14,155	-22%	-$205K	0.91%	41
2017 Q1	$948K	Buy	63,193 +16,032	+34%	+$222K	1.15%	33
2016 Q4	$618K	Sell	47,161 -9,097	-16%	-$143K	0.82%	41
2016 Q3	$969K	Buy	56,258 +7,979	+17%	+$148K	1.44%	26
2016 Q2	$871K	Sell	48,279 -770	-2%	-$15K	1.42%	31
2016 Q1	$931K	Buy	49,049 +2,111	+4%	+$41.6K	1.52%	24
2015 Q4	$1.25M	Sell	46,938 -5,009	-10%	-$134K	2.05%	16
2015 Q3	$1.27M	Buy	51,947 +22,542	+77%	+$751K	1.92%	19
2015 Q2	$916K	Buy	+29,405	New	+$553K	1.29%	32

Other funds holding HRTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Partner Investment Management's HRTX Position: Q3 2017 in Review

Partner Investment Management sold out of Heron Therapeutics (HRTX) in Q3 2017, closing a stake of 49,038 shares — an estimated $679K sold.

Partner Investment Management first reported a position in HRTX in Q2 2015 and held it in 9 quarters. The position peaked at $1.27M in Q3 2015. 104 funds tracked by Wall St. Rank hold HRTX as of Q3 2017.

Partner Investment Management reported no remaining Heron Therapeutics position as of Q3 2017 after selling out during the quarter.
Partner Investment Management sold 49,038 Heron Therapeutics shares in Q3 2017, an estimated $679K.
Partner Investment Management first reported a position in Heron Therapeutics in Q2 2015 and held it in 9 quarters.
Partner Investment Management's Heron Therapeutics position peaked at $1.27M in Q3 2015.
104 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2017.

Based on Partner Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.